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Ibogaine Noribogaine Morphine
Locomotor activity Sex differences Route of administration IBOGAINE, a naturally-occurring indole alkaloid, is currently being investigated as an antiaddictive agent. Anecdotal reports in humans suggest that a single dose of ibogaine can interrupt drug-seeking behavior in addicts for up to 6 months. In rats, ibogaine has been shown to produce prolonged decreases in morphine (5) and cocaine (2,7) self-administration.
Ibogaine has also been reported to antagonize morphineinduced dopamine release (14) and to antagonize morphineinduced locomotor activity in rats (1519). The mechanism of action of ibogaine has yet to be determined. Based on studies of ibogaine affinity, ibogaine's mechanism may involve the kappa opioid receptor (3,18.22,24) the NMDA subtype of glutamate receptor (8, 17, 19, 20, 21, 24) , or the serotonin transporter (16, 24) . A metabolite of ibogaine, noribogaine (16) , has also been shown to have affinity for these receptors (16, 17, 18) . Noribogaine (12 hydroxyibogamine), like its parent compound, acutely decreases dopamine release in the nucleus accumbens, antagonizes morphine-induced locomotor activity, and decreases morphine and cocaine selfadministration (9) . Elevated plasma levels of noribogaine were reported to persist for up to 24 h in humans after ibogaine administration in a representative male subject (16) . Based on these results and the in vitro binding activity of noribogaine, it was speculated that noribogaine is responsible for the longlasting effects of ibogaine (16) . Recently, this laboratory has developed sensitive and specific methods utilizing gas chromatography-mass spectrometry (GCMS) for measuring ibogaine (4) and noribogaine (Hough et al., in preparation) . Using the latter method, we detected noribogaine in rats up to several h following ibogaine administration (Hough et al., in preparation).
To date no studies have been performed which examine the effects of ibogaine in male versus female rats, despite an early report that the bioavailability of ibogaine may be higher in female than in male rats (12) . Therefore, in the present study we wanted to determine if there are sex differences in the locomotor response of rats to ibogaine and in the ability of ibogaine to antagonize morphine-induced locomotor activity. Opioid-induced locomotor activity is thought to be correlated with changes in nucleus accumbens dopamine (13) . Furthermore, using GCMS, we sought to determine if the levels of ibogaine and/or noribogaine in whole brain and plasma differ between the sexes in ibogaine-treated rats.
The influence of route of administration on ibogaine activity has yet to be determined, although it has been demonstrated previously (11) that ibogaine levels in whole brain and plasma of ibogaine-treated rats are significantly greater if ibogaine is administered subcutaneously rather than intraperitoneally. Thus, we also wanted to determine the effect of route of administration on ibogaine antagonism of morphine in both sexes.
METHOD

Animals
Female (250-275 g) and male (275-300 g) Sprague-Dawley rats (Taconic, Germantown, NY) were housed in groups of 3-4 and allowed food and water ad lib. The animals were maintained on a 12 h light cycle (lights on at 0700) in a room carefully controlled for heat and humidity. Each rat received only 1 dose of ibogaine, noribogaine or saline and were challenged with either saline or morphine. It should be noted that ibogaine produces whole body tremors in both sexes, but which appear to be more severe in females than in males, lasting 3-4 h after administration, thus making locomotor activity difficult to monitor until at least 5 h after administration. Since noribogaine does not produce noticeable tremors in either sex, activity studies could be performed 1 h after its administration. Immediately following the morphine or saline challenge injection locomotor activity was monitored for 3 h. It should also be noted that ibogaine has previously been shown to not influence morphine metabolism (6) , and morphine pretreatment has been shown to not influence ibogaine metabolism (19) .
Activity Measurements
Locomotor studies were performed in cylindrical (60 cm) photocell activity cages with three intersecting light beams.
Each time a light beam was broken a single activity count was recorded by a 386 computer with Med Associates software. Each experiment was begun immediately following the saline (1 mgiml, IP) or morphine challenge (5 mg/kg, IP). (middle and bottom panels), whereas noribogaine or saline was administered 1 h before a saline challenge (top panels). There are at least 4 rats per group and *denotes significant difference from the saline-saline control group of the same sex.
from J + W Scientific, Folsom, CA). The GC injector, oven, and detector temperatures were 210", 90", and 335°C respectively. Separation of the noribogaine and nortabernanthine derivatives was accomplished by a temperature program starting at 90°C for 1 min (1 min purge delay), increasing by 7OW min to a temperature of 230°C thereafter at OS"C/min to a temperature of 240°C followed by 70"C/min to a final temperature of 325°C which was held for 5 min. Electron impact mass spectra were obtained (-70 eV); computerized data analysis was performed with HP ChemStation software. Noribogaine and nortabernanthine derivatives were detected and quantified by monitoring the molecular ion (M+) of both derivatives (HFB-noribogaine and HFB-nortabernanthine, respectively, both at m/e 492), which eluted at 11.2 and 11.5 min, respectively. Monitoring of m/e 407 (35 ~tl 20% of M+) was also performed to confirm all peak identities. In the presently described experiments, unknown samples were solved from standard curves which were linear from 50-1000 ng of noribogaine. nificant Difference (LSD) post hoc tests were performed (Statistica). GCMS data at 1 and 5 h were analyzed with ANOVA followed by LSD post hoc tests, GCMS data at 19 h were analyzed with a Kruskal-Wallis ANOVA by rank because some samples were not detectable at this time point.
RESULTS
Basal locomotor activity (i.e. following a saline injection)
did not differ between the sexes at any time point (Fig. 1) . One The levels of ibogaine in whole brain and in plasma of ibogaine-treated rats were greater in female than in male rats 1 h after ibogaine administration (LSD test (p < 0.05, Figs. 5 and 6) . The whole brain ibogaine levels illustrated in Figure  5 correspond approximately to 10, 1 and 0.7 p,M in females and 6, 0.9 and 0.2 PM in males at 1, 5 and 19 h, respectively. Plasma ibogaine levels (Fig. 6) correspond to approximately 0.5 and 0.3 PM in females and males, respectively, at 1 h following ibogaine administration. Female brain and plasma levels of ibogaine at 1 h agree with previously published data (10) . Plasma levels of ibogaine at 5 and 19 h were below the limit of detection (data not shown).
Brain and plasma levels of noribogaine were greater in 
DISCUSSION
The present study shows that ibogaine influences locomotor activity differently in female and male rats, and that these effects are not due to changes in basal levels of activity between the sexes. In addition, ibogaine antagonism of morphineinduced locomotor activity occurs to a greater extent in female than in male rats (1, 5 and 19 h) and whole brain and plasma levels of ibogaine (1 h) and noribogaine (5 h) are greater in female than in male rats. Since there are such high levels of noribogaine as compared to ibogaine in the brain (Fig. 5) , this finding also suggests that noribogaine is, in fact, a major metabolite of ibogaine in rats and may contribute significantly to ibogaine's effects.
The differences in ibogaine levels seen 1 h after administration suggest that the amount of ibogaine reaching the plasma and brain compartments is greater in female than in male rats. This likely reflects a greater bioavailability of ibogaine in females as compared to males, as has been previously reported (12) .
Our studies also show that there is a sex difference (females > males) in noribogaine 5 h after ibogaine administraq SALINE (IP+SC) c] IBOGAINE IP El LBOGAINJZSC levels at 19 h but others (16) report persisting high levels of noribogaine at 24 h may be due to differences in species, GCMS methods or doses and routes of administration. As we have demonstrated here (Fig. 6 ) and as has been previously shown (11) . route of administration plays an important role in determining both the ability of ibogaine to antagonize morphine and the level of ibogaine in tissues and in plasma. Our data showing that subcutaneous administration of ibogaine produces a greater antagonism of morphine is likely the result of higher levels of ibogaine in the brain and plasma following subcutaneous administration as compared to the intraperitoneal route (11) . The control group is a combination of rats which received saline either SC or IP, there was no difference between the groups. There are at least 8 rats per group and *denotes significant difference from the saline group of the same sex.
at high levels in the plasma of ibogaine-treated humans for at least 24 h (16). In the present study, neither ibogaine nor noribogaine persisted at high levels in either plasma or brain of rats 19 h following the administration of ibogaine. The amount of ibogaine and noribogaine remaining 19 h after ibogaine administration, however, may still produce pharmacological actions at the kappa and NMDA receptors, or at the serotonin transporter, putative sites of ibogaine action.
The reason that we find substantiaIly diminished noribogaine Why ibogaine levels differ between the sexes is not known at this time. However, the differences could be due to sex hormones and their interactions with enzymes involved with ibogaine metabolism. The 0-demethylation of ibogaine to noribogaine in the body presumably involves a P4jO cytochrome. P450 cytochromes have been demonstrated to produce sex-dependent effects. For example, it has been previously reported that mouse renal P450 levels are regulated by androgens (10) and that expression of rat hepatic P450 cytochromes are regulated by sex hormones (1, 23) . It thus seems possible that the P450 enzyme involved in ibogaine's metabolism could be one which is influenced by sex hormones and may contribute to the difference in drug levels reported presently.
In this study, it was interesting to note that low doses of both ibogaine and noribogaine produced a potentiation of morphine-induced locomotor activity in males (Figs. 2 and 3 ).
It appears that this potentiation does not occur in females, even at very low doses, as we have subsequently tested a very low dose of ibogaine (2.5 mg/kg, IP) and found that it had no effect on morphine-induced locomotor activity (data not shown). This suggests that in male rats ibogaine produces biphasic effects on morphine, with potentiation of morphine actions occurring at low doses and antagonism occurring at higher doses of ibogaine. Of course, it is possible that ibogaine also produces biphasic effects on morphine responses in female rats, but that the stimulatory effect may be masked by a more predominant antagonistic effect in females.
The present data are consistent with a previous study (12) which reported that "peak plasma levels" of ibogaine, following oral [jH]ibogaine administration, were approximately three-fold higher in females than in males, and that the bioavailability of ibogaine was approximately two-fold higher in female than in male CD rats.
The present study shows that there are substantial sex differences in both ibogaine levels in the brain and plasma and in the ability of ibogaine to antagonize morphine. The importance of this finding in terms of the clinical use of ibogaine as an antiaddictive agent warrants further study.
